Development of a small molecule BAG1 inhibitor for estrogen receptor positive breast cancer therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Karlsruhe, Karlsruher Institut für Technologie (KIT), Dissertation, 2022
- Keyword
-
Brustkrebs
Krebs
Molekularbiologie
Östrogene
Protein p53
- Event
-
Veröffentlichung
- (where)
-
Karlsruhe
- (who)
-
KIT-Bibliothek
- (when)
-
2023
- Creator
- Contributor
-
Cato, Andrew C.
Bastmeyer, Martin
- DOI
-
10.5445/IR/1000152551
- URN
-
urn:nbn:de:101:1-2024010303593176298081
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pan, Mengwu
- Cato, Andrew C.
- Bastmeyer, Martin
- KIT-Bibliothek
Time of origin
- 2023
Other Objects (12)
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer
Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
The impact of CBP expression in estrogen receptor-positive breast cancer
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer
Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
The impact of CBP expression in estrogen receptor-positive breast cancer
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer
Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype